Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Aripiprazole/lurasidone

Somnolence, lack of efficacy and off-label use: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ricci V, et al. Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report. International Journal of Environmental Research and Public Health 19 : 16057, No. 23, Dec 2022. Available from: URL: http://doi.org/10.3390/ijerph192316057 Ricci V, et al. Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report. International Journal of Environmental Research and Public Health 19 : 16057, No. 23, Dec 2022. Available from: URL: http://​doi.​org/​10.​3390/​ijerph192316057
Metadaten
Titel
Aripiprazole/lurasidone
Somnolence, lack of efficacy and off-label use: case report
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-43521-1

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Elasomeran

Case report

Elvitegravir

Case report

Atezolizumab

Case report

Brolucizumab

Case report

Heparin